object
studi
evalu
passiv
protect
effici
immunoglobulin
yolk
igi
specif
human
enteroviru
type
antibodi
rais
intramuscular
immun
white
leghorn
hen
inactiv
human
serv
antigen
titer
specif
antibodi
analyz
purifi
igi
egg
yolk
immun
hen
result
indic
titer
igi
specif
increas
third
week
first
immun
content
total
igi
mgyolk
averag
concentr
specif
igi
mgyolk
egg
wk
immun
result
neutral
effect
specif
igi
mice
demonstr
igi
either
intraperiton
inject
oral
administr
abl
significantli
reduc
morbid
mortal
infect
mice
pup
research
extens
studi
passiv
immun
human
anim
use
specif
antibodi
protect
pathogen
increas
antibioticresist
bacteria
desir
treat
pathogen
respond
antibiot
viral
pathogen
prompt
mani
research
use
antibodi
altern
antibiot
igi
immunoglobulin
yolk
antibodi
predomin
serum
immunoglobulin
bird
reptil
amphibian
transfer
serum
egg
yolk
femal
confer
passiv
immun
embryo
neonat
potenti
oral
administ
igi
prevent
treatment
mani
pathogen
studi
mani
year
escherichia
coli
helicobact
pylori
salmonella
rotaviru
staphylococcu
streptococcu
mutan
yersinia
coronaviru
porcin
epidem
diarrhea
viru
paper
evalu
effici
igi
enteroviru
enteroviru
belong
human
enteroviru
famili
picornavirida
virion
consist
nonenvelop
capsid
surround
core
singlestrand
positivepolar
rna
approxim
kb
size
sinc
initi
descript
outbreak
viru
identifi
period
countri
throughout
world
includ
usa
australia
sweden
japan
bulgaria
hungari
hong
kong
malaysia
outbreak
infect
occur
taiwan
children
hospit
die
infect
gener
mild
like
handfootandmouth
diseas
hfmd
herpangina
occasion
lead
sever
diseas
asept
mening
poliomyelitislik
paralysi
even
fatal
enceph
neonat
recent
year
effort
made
control
infect
promis
antivir
agent
wingroup
compound
undergon
clinic
trial
addit
research
group
taiwan
develop
two
candid
vaccin
includ
formalininactiv
whole
viru
vaccin
express
dna
vaccin
efficaci
vaccin
construct
current
test
anim
model
sever
approach
attempt
treatment
viral
diseas
research
tri
block
replic
viru
bind
capsid
viru
chemic
pyridazinamin
phenoxyl
imidazol
pleconaril
howev
treatment
pleconaril
signific
bind
pleconaril
capsid
limit
higher
viral
concentr
vitro
specif
antibodi
could
bind
viru
henc
reduc
contact
viru
host
cell
altern
choic
human
immunoglobulin
appli
treatment
infect
babi
whose
immun
system
welldevelop
routin
therapi
treatment
infect
human
immunoglobulin
far
howev
anim
model
challeng
mous
develop
provid
inform
protect
effect
neutral
antibodi
infect
compar
tradit
antibodi
product
chicken
biofactori
produc
higher
yield
igi
antibodi
mammal
igg
chicken
lay
egg
year
egg
yolk
contain
mg
igi
antibodi
studi
subject
produc
igi
enteroviru
igi
evalu
inhibit
effect
specif
igi
includ
vitro
viru
neutral
test
vivo
icr
mice
model
studi
also
provid
anim
model
applic
igi
cure
prevent
strain
strain
origin
deriv
patient
enceph
strain
mouseadapt
enteroviru
increas
virul
mice
gener
four
serial
passag
strain
stock
viru
strain
grown
rd
rhabdomyosarcoma
cell
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
usa
contain
fetal
bovin
serum
fb
invitrogen
usa
mm
lglutamin
invitrogen
usa
iuml
penicillin
invitrogen
usa
gml
streptomycin
invitrogen
usa
anim
receiv
human
care
outlin
guid
care
use
experiment
anim
viral
challeng
institut
anim
care
use
committe
iacuc
approv
four
white
leghorn
lay
hen
obtain
livestock
research
institut
council
agricultur
execut
yuan
taiwan
util
product
igi
formalininactiv
strain
util
antigen
one
millilit
antigen
gml
pfu
emulsifi
equal
volum
freund
complet
adjuv
immun
intramuscularli
chicken
site
breast
muscl
four
booster
inject
freund
incomplet
adjuv
given
week
first
immun
egg
collect
daili
first
day
week
last
immun
store
c
egg
yolk
separ
pool
kept
c
prior
igi
purif
egg
yolk
chicken
week
pool
one
analysi
sampl
isol
igi
carri
describ
akita
nakai
modif
egg
yolk
first
mix
one
nine
volum
cold
distil
water
acidifi
n
hcl
ph
store
overnight
c
mixtur
centrifug
g
c
min
obtain
water
solubl
fraction
wsf
wsf
collect
filter
remov
solid
result
igycontain
wsf
purifi
ultra
filtrat
use
amicon
filter
millipor
condens
sampl
origin
volum
wsf
concentr
subject
viru
neutral
test
mice
challeng
experi
antibodi
activ
igi
determin
use
elisa
method
describ
lee
et
al
modif
briefli
microtit
plate
coat
l
inactiv
antigen
gwell
control
well
coat
rabbit
antichicken
igi
antibodi
gml
sigma
plate
incub
overnight
c
wash
pbstween
buffer
bsa
block
conduct
overnight
c
well
wash
pbstween
buffer
next
dilut
wsf
ad
sampl
well
lwell
test
wsf
chicken
immun
use
control
gener
standard
curv
well
fill
l
serialdilut
pure
chicken
igi
concentr
gml
gml
promega
incub
c
overnight
wash
pbstween
buffer
l
alkalin
phosphateconjug
goat
antichicken
igi
promega
ad
well
incub
c
h
wash
pbstween
buffer
l
disodium
pnitrophenyl
phosphat
ad
well
substrat
sigma
allow
react
c
min
absorb
measur
nm
use
micropl
reader
multiskan
ms
thermo
labsystem
result
absorb
standard
curv
provid
rel
measur
igi
concentr
total
igi
determin
well
microtit
plate
first
coat
l
rabbit
antichicken
igi
antibodi
gml
sigma
l
dilut
wsf
ad
follow
experi
perform
follow
protocol
describ
run
sdspolyacrylamid
gel
electrophoresi
sdspage
transfer
electr
onto
nitrocellulos
membran
membran
divid
part
soak
block
buffer
nonfat
dri
milk
tbst
min
room
temperatur
incub
nonspecif
igi
h
wash
time
tbst
membran
incub
peroxidaseconjug
goat
antichicken
igi
dilut
block
buffer
room
temperatur
h
immunoreact
detect
incub
membran
wv
tb
vv
h
tcid
viru
neutral
titer
igi
determin
use
method
describ
yu
et
al
tcid
test
rd
cell
ad
micropl
well
follow
serial
dilut
viru
tissu
cultur
infect
dose
determin
incub
co
c
day
neutral
test
l
sampl
serial
dilut
igi
concentr
solut
mix
l
tcid
micropl
well
two
hour
later
rd
cell
suspens
cellwel
ad
incub
c
co
day
neutral
antibodi
titer
identifi
highest
dilut
purifi
igi
solut
complet
inhibit
viru
growth
challeng
test
mous
model
studi
modifi
wang
et
al
trial
design
test
effect
igi
differ
neutral
titer
mortal
suckl
mice
onedayold
icr
strain
mous
intraperiton
ip
inocul
pfu
viru
mouseadapt
strain
thereaft
igi
differ
neutral
titer
inject
ip
challeng
mice
day
inocul
dpi
dosag
igi
week
immun
mg
igi
l
per
mous
trial
igi
treatment
date
dpi
dpi
respect
trial
use
evalu
protect
effect
igi
oral
treatment
specif
trial
use
feed
tube
oral
inocul
mice
g
old
g
respect
mice
given
l
viru
pfumous
fast
pup
l
igi
titer
oral
administ
either
h
h
viral
challeng
mice
check
daili
bodi
weight
syndrom
infect
includ
limb
paralysi
abnorm
hair
coat
week
viral
infect
morbid
mortal
data
collect
two
week
viral
challeng
concentr
total
igi
specif
igi
analyz
elisa
content
igi
wsf
egg
yolk
investig
period
week
first
week
immun
week
last
booster
inject
averag
content
total
igi
yolk
mg
tabl
egg
yolk
total
protein
condens
ultrafiltr
total
protein
per
egg
mg
averag
puriti
total
igi
increas
content
specif
igi
increas
gradual
third
week
first
immun
fig
indic
variat
immun
respons
among
individu
hen
notic
larg
standard
deviat
averag
igi
concentr
reach
mg
per
yolk
third
eighteenth
week
equival
total
igi
neutral
titer
specif
igi
determin
cytopath
effect
cpe
rd
cell
fig
result
neutral
titer
specif
igi
obtain
egg
immun
chicken
rang
data
shown
compar
neutral
titer
content
specif
igi
respect
yolk
show
signific
cor
b
igycontain
wsf
purifi
ultra
filtrat
use
amicon
filter
millipor
condens
sampl
origin
volum
wsf
concentr
subject
viru
neutral
test
relat
two
set
data
r
data
shown
western
blot
analysi
immunoreact
igi
run
sdspage
transfer
onto
nitrocellulos
filter
probe
immun
nonimmun
igi
detect
kda
molecular
mass
fig
igi
specif
bound
protein
witch
molecular
weight
correspond
viru
fig
first
part
anim
test
icr
mice
show
limb
paralysi
abnorm
hair
growth
challeng
ip
model
fig
trial
conduct
investig
effect
ip
inject
specif
igi
cure
ip
mice
tabl
onedayold
icr
mice
challeng
strain
dose
pfu
per
mous
averag
morbid
control
group
result
mortal
base
challeng
mice
base
ill
mice
inject
nonimmun
igi
tabl
ip
administr
purifi
specif
igi
deriv
condens
immun
yolk
wsf
mice
administr
appli
continu
day
day
viral
infect
dpi
third
day
post
infect
dpi
therapeut
effect
igi
vari
accord
neutral
titer
specif
igi
administ
infect
rate
titer
specif
igi
infect
rate
control
group
tabl
treatment
igi
titer
significantli
reduc
mortal
trial
howev
igi
titer
higher
morbid
reduc
respect
igi
treat
group
titer
group
titer
trial
death
viral
infect
igi
inject
mortal
rate
without
treatment
specif
igi
challeng
mice
show
high
morbid
mortal
trial
treatment
c
nonimmun
igi
differ
proport
morbid
mortal
test
use
x
statist
p
time
specif
igi
began
dpi
morbid
increas
respect
reduct
cure
effect
increas
mortal
respect
mortal
mice
show
ill
trial
respect
indic
decreas
cure
effect
specif
igi
follow
delay
igi
administr
one
day
second
part
anim
test
involv
oral
administr
specif
igi
oral
challeng
mice
trial
dosag
pfu
strain
oral
fed
pup
day
old
bodi
weight
g
result
indic
l
specif
igi
oral
fed
h
viral
challeng
morbid
mortal
challeng
mice
respect
morbid
mortal
significantli
reduc
compar
control
group
respect
tabl
specif
igi
given
pup
h
viral
challeng
infect
rate
final
mortal
rate
morbid
mortal
rate
specif
igi
treatment
group
lower
control
group
regardless
whether
igi
fed
h
viral
challeng
viru
neutral
specif
igi
effect
compar
mortal
mice
exhibit
infect
symptom
igi
treat
group
show
similar
rate
control
group
exceed
igi
applic
trial
similar
trial
chang
age
challeng
pup
old
bodi
weight
rang
g
situat
averag
infect
rate
decreas
igi
treat
group
control
group
also
mortal
igi
treat
group
among
ill
pup
lower
control
group
although
averag
mortal
igi
treat
group
low
control
group
also
exhibit
lower
mortal
control
group
trial
recent
year
pathogenspecif
igi
also
demonstr
effect
passiv
protect
human
diseas
staphylococcu
holotoxin
rotaviru
diarrhea
dental
cari
caus
mutan
h
pylori
gastric
ulcer
studi
tri
produc
specif
igi
human
enteroviru
first
report
unit
state
subsequ
report
worldwid
taiwan
sever
case
human
report
everi
year
devast
outbreak
serious
infect
lie
complic
includ
handfootandmouth
diseas
herpangina
asept
mening
poliomyelitislik
paralysi
fatal
enceph
fatal
case
occur
children
year
old
high
mortal
correl
brainstem
enceph
specif
igi
egg
yolk
increas
third
week
first
immun
though
obviou
differ
among
individu
hen
variat
antibodi
product
base
specif
igi
product
might
result
differ
individu
immun
respons
origin
antigen
also
play
import
role
immun
respons
differ
outer
membran
protein
fimbrial
adhes
bacteria
affect
rate
igi
product
protein
antigen
contain
whole
bacteria
viru
achiev
better
specif
antibodi
product
vivo
neutral
effect
result
antibodi
also
better
studi
use
whole
viru
antigen
sourc
obtain
better
igi
titer
total
protein
obtain
egg
yolk
water
dilut
method
around
mg
per
egg
protein
contain
lipid
lipoprotein
account
onesixth
total
protein
yolk
studi
puriti
igi
wsf
approxim
tabl
demonstr
water
dilut
method
easili
separ
igi
egg
yolk
compon
describ
previous
product
igi
trial
immun
dosag
antigen
use
doubl
immun
schedul
modifi
longer
interv
week
appli
fourth
immun
last
boost
given
week
thirteen
thereaft
averag
specificigi
week
increas
total
igi
significantli
higher
pretest
total
igi
p
howev
whether
modifi
protocol
benefici
product
specif
igi
remain
clarifi
analysi
relationship
concentr
specif
igi
neutral
titer
sampl
reveal
signific
correl
tabl
indic
amount
specif
igi
estim
elisa
method
good
indic
neutral
titer
viru
studi
previou
studi
effect
antibodi
bacillu
spore
botulinum
pentaval
abcd
toxoid
anthrax
vaccin
also
suggest
elisa
reliabl
indic
neutral
titer
neutral
titer
better
indic
antibodi
function
determin
concentr
specif
igi
elisa
method
use
cell
lysat
whole
viru
particl
coat
antigen
bind
viral
protein
specif
igi
would
count
part
igi
concentr
whether
specif
antibodi
effect
viru
neutral
kovacsnolan
et
al
studi
epitop
human
rotaviru
hrv
igi
found
three
five
sequenti
neutral
epitop
wa
strain
subunit
protein
directli
involv
hrv
neutral
result
indic
therapeut
function
signific
neutral
titer
igi
higher
tabl
howev
research
necessari
identifi
antibodi
directli
involv
neutral
studi
includ
two
panel
anim
test
challeng
igi
treatment
trial
challeng
mice
mouseadapt
strain
intraperiton
administ
dosag
pfu
per
mous
treat
specif
igi
neutral
titer
result
reveal
therapeut
effect
contrari
neutral
titer
valu
specif
igi
higher
protect
effect
signific
tabl
previou
studi
also
show
level
neutral
titer
effect
serum
igg
mice
compar
control
group
mice
specif
igi
treat
group
lower
mortal
also
normal
weight
gain
mice
control
group
show
weight
loss
day
viral
challeng
continu
lose
bodi
weight
die
less
sick
mice
control
group
surviv
artifici
infect
dose
pfu
per
mous
surviv
mice
gain
weight
despit
show
sign
ill
reach
bodi
weight
g
recov
infect
return
healthi
statu
howev
subsequ
weight
gain
mice
specif
igi
treat
group
data
shown
surviv
mice
also
exhibit
persist
paralysi
hind
limb
remain
paralyz
rest
live
like
children
infect
trial
ip
inject
time
specif
igi
began
second
day
viral
infect
last
three
consecut
day
syndrom
appear
practic
situat
children
infect
probabl
receiv
igg
treatment
exhibit
typic
symptom
determin
critic
time
effect
treatment
trial
appli
specif
igi
treatment
one
two
day
later
respect
clearli
start
time
specif
igi
inject
essenti
reduc
mortal
infect
mice
igi
given
dpi
point
mice
exhibit
symptom
hind
limb
paralysi
infect
mice
surviv
report
first
day
infect
viru
kept
small
intestin
spread
organ
dpi
viru
attack
organ
dpi
includ
brain
stem
lung
spinal
cord
muscl
start
specif
igi
treatment
dpi
correspond
onset
clinic
symptom
children
therapeut
outcom
improv
case
surviv
rate
mice
could
increas
highlight
import
time
specif
igi
treatment
onset
clinic
symptom
specif
igi
treatment
better
chanc
achiev
effect
therapi
anim
studi
use
oral
feed
egg
yolk
powder
directli
without
purif
specif
antibodi
yolk
studi
prove
possibl
passiv
protect
de
novo
form
yolk
powder
studi
dayold
mice
oral
challeng
viral
dosag
pfu
per
mous
challeng
mice
specif
igytr
group
show
lower
morbid
rate
control
group
show
morbid
rate
indic
oral
fed
specif
igi
effect
neutral
viral
attack
gastroenter
duct
therebi
block
infect
viru
challeng
mice
neutral
function
appear
effect
matter
given
h
viral
challeng
mortal
among
specif
igi
treat
mice
significantli
lower
control
group
howev
effect
specif
igi
declin
pup
age
day
old
bodi
weight
rang
g
previou
research
also
show
age
mice
affect
infect
result
mice
day
old
would
infect
artifici
challeng
indic
immun
system
mice
age
could
provid
suitabl
protect
mice
challeng
oral
receiv
igi
oral
passag
viru
igi
pass
gastroenter
duct
digest
gastric
juic
reduc
viral
infect
igi
function
notic
lower
morbid
oral
challeng
strain
less
protect
function
igi
among
infect
mice
compar
result
trial
infect
rate
near
cure
function
obtain
igi
specif
human
rotaviru
exhibit
passiv
protect
diarrhea
mice
although
gastric
juic
influenc
igi
still
protect
suffici
amount
igi
provid
oral
administr
spray
dri
yolk
antibodi
specif
salmonella
typhimurium
salmonella
dublin
effect
prevent
salmonella
infect
calv
igi
rais
etec
antigen
also
proven
effect
control
diarrhea
piglet
oral
administr
nevertheless
dayold
mice
pup
studi
could
consum
egg
yolk
appli
purifi
antibodi
igi
instead
purifi
igi
deriv
water
solubl
fraction
egg
yolk
access
gastric
juic
easili
expos
digest
enzym
activ
might
influenc
chang
structur
loss
bioactiv
base
limit
oral
administr
suckl
pup
higher
titer
igi
continu
treatment
igi
viral
challeng
might
achiev
greater
protect
possibl
worthi
research
result
studi
howev
indic
potenti
igi
prevent
infect
young
children
sever
studi
conduct
evalu
stabil
antibodi
igi
degrad
pasteur
c
igi
stabl
min
c
longer
activ
min
c
igi
technolog
new
potenti
market
applic
medicin
public
health
veterinari
medicin
food
safeti
broader
use
igi
technolog
could
appli
biolog
diagnost
tool
nutraceut
function
food
develop
oralsupplement
prophylaxi
pathogenspecif
antimicrobi
agent
infecti
diseas
control
conclus
icr
mice
ip
challeng
mouseadapt
strain
dose
pfu
per
mous
induc
infect
result
high
mortal
rate
howev
surviv
rate
achiev
challeng
mice
ip
inject
dpi
consecut
day
purifi
igi
antibodi
neutral
titer
challeng
carri
oral
dose
pfu
per
mous
lower
morbid
igi
treat
group
prove
protect
could
achiev
neutral
viru
gastroenter
duct
therebi
reduc
mortal
challeng
mice
first
studi
evalu
effect
igi
treatment
infect
posit
result
indic
applic
prevent
possibl
form
eggyolkad
drink
yolk
powder
tablet
capsul
potenti
use
prevent
earli
infect
